The promise and challenges of targeting RSK for the treatment of cancer. (Q50787038)

19 March 2018

title

The promise and challenges of targeting RSK for the treatment of cancer. (English)

1 reference

19 March 2018

author name string

Anna L Stratford

series ordinal

1

1 reference

19 March 2018

Sandra E Dunn

series ordinal

2

1 reference

19 March 2018

language of work or name

English

0 references

publication date

1 January 2011

1 reference

19 March 2018

Expert Opinion on Therapeutic Targets

published in

1 reference

19 March 2018

volume

15

1 reference

19 March 2018

issue

1

1 reference

19 March 2018

page(s)

1-4

1 reference

19 March 2018

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Targeting RSK2 in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

The RSK family of kinases: emerging roles in cellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Structural Diversity of the Active N-Terminal Kinase Domain of p90 Ribosomal S6 Kinase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Altered extracellular signal-regulated kinase signaling and glycogen metabolism in skeletal muscle from p90 ribosomal S6 kinase 2 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Insulin resistance and lipodystrophy in mice lacking ribosomal S6 kinase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

Critical role for Rsk2 in T-lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

A clickable inhibitor reveals context-dependent autoactivation of p90 RSK

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.537656

10.1517/14728222.2011.537656

21 January 2018

Identifiers

DOI

1 reference

19 March 2018

1 reference

19 March 2018